Press release
Investigation announced for Investors who lost money with shares of Anavex Life Sciences Corp. (NASDAQ: AVXL)
An investigation for investors in Anavex Life Sciences Corp. (NASDAQ: AVXL) shares over potential securities laws violations.
Investors who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether certain statements by Anavex Life Sciences Corp. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
New York based Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases.
Before the market opened on February 1, 2022, Anavex Life Sciences Corp. announced that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoints. Following the announcement, several people on social media indicated that the primary and secondary endpoints were recently changed. STAT's Adam Feuerstein tweeted, "Anavex changed the primary and secondary endpoints of this Rett study on Jan. 18, allowing it to claim success when the drug most likely failed."
On December 2, 2022, Anavex Life Sciences Corp. announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company's claim noting "there are several key factors that point us to believe the data is provocative, but not yet compelling, given the choice of statistical analyses and other trial design/conduct 'complexifiers'." Additionally, a biotech journalist commented on AVXL's findings stating "[w]hat sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials…Anavex announced "positive" outcomes from studies of its drug called blarcamesine - except the results were derived from efficacy endpoints that were not part of the original study designs."
On January 3, 2024, Anavex Life Sciences Corp. announced that results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome failed to show statistical significance towards its primary endpoints. Biotech analysts commented that "the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results."
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) declined from $19.83 per share in December 2021 to as low as $4.80 per share on February 26, 2024.
Those who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who lost money with shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) here
News-ID: 3416030 • Views: …
More Releases from Shareholders Foundation
Investigation announced for Investors in FMC Corporation (NYSE: FMC) over potent …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of FMC Corporation.
Investors who are current long term investors in FMC Corporation (NYSE: FMC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: FMC stocks follows a lawsuit filed against FMC Corporation over…
Investigation announced for Long-Term Investors who lost money with Advance Auto …
An investigation was announced for long-term investors in shares of Advance Auto Parts, Inc. (NYSE: AAP) concerning potential breaches of fiduciary duties by certain directors of Advance Auto Parts, Inc.
Investors who are current long term investors in Advance Auto Parts, Inc. (NYSE: AAP) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
Investigation announced for Investors in Treace Medical Concepts, Inc. (NASDAQ: …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Treace Medical Concepts, Inc.
Investors who purchased shares of Treace Medical Concepts, Inc. (NASDAQ: TMCI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Treace Medical Concepts, Inc. directors breached their fiduciary duties and caused damage to the company and its…
Deadline on May 20th coming up in Lawsuit for Investors in the Chemours Company …
A deadline is coming up on May 20, 2024 in the lawsuit filed for certain investors of The Chemours Company (NYSE: CC) over alleged securities laws violations by The Chemours Company.
Investors who purchased shares of The Chemours Company (NYSE: CC) have certain options and there are strict and short deadlines running. Deadline: May 20, 2024. NYSE: CC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Anavex
Investigation announced for NASDAQ:AVXL Investors over possible Wrongdoing at An …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Anavex Life Sciences Corp.
Investors who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Anavex Life Sciences directors breached their fiduciary duties and caused damage to the company and…
Investigation for Investors in NASDAW: AVXL shares over potential Securities Law …
An investigation on behalf of investors of Anavex Life Sciences Corp. (NASDAQ: AVXL) shares over potential securities laws violations by Anavex Life Sciences Corp. and certain of its directors and officers in connection with certain financial statements was announced.
Investors who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law…
Rett Syndrome Market Future Scope, Industry Growth, Demand, Region, Competitive …
LOS ANGELES, United States: The research study presented in this report offers a complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the global Rett Syndrome market. It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Rett Syndrome market. The authors of the report have segmented the global Rett Syndrome market as…
Progesterone Receptor Agonist Market 2020 Research and Clinical Analysis– Ther …
Progesterone Receptor Agonist -Pipeline Insight, 2020
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Progesterone Receptor Agonist Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally.…
Rett Syndrome Treatment Market 2020 Size, Share, Trends Analysis 2027 Pointing t …
The Objective of Rett Syndrome Treatment Market Research Report is to provide a detailed analysis of industry and its impact based on applications and on different geographical regions, strategically analyses the growth trends, future prospects. Rett Syndrome Treatment Market Research Report is an in-depth evaluation of this industry, and a commendable brief of its segmentation. This report provides a basic overview of the market with respect to its current status…
Pain Drug Development Pipeline Review 2018 - Abide Therapeutics, Abiogen Pharma, …
Pain Drug Development Pipeline Review, 2018
Summary
This report provides an overview of the pipeline landscape for pain disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-operative pain, fibromyalgia, complex regional pain syndrome (CRPS) and visceral pain, and features dormant and discontinued products.
Pain is one of the main post-operative adverse outcomes causing distress to patients. Causes of post-operative pain include peripheral nerve…
